Expert���s Corner

Advertisement

Advertisement



Sep
23
Today In Oncology
Olaparib Receives Positive pCODR Recommendation for Treatment of BRCA-Mutated Ovarian Cancer
Durvalumab Consolidation After Chemoradiotherapy in Stage III NSCLC
Adjuvant Nivolumab vs Ipilimumab in Resected Stage III or IV Melanoma
Preexisting Dementia and Survival in Older Patients With Stage III Colon Cancer
Tibetan Yoga Practice May Improve Sleep Quality for Patients With Breast Cancer Undergoing Chemotherapy
Positive Results from Phase III MURANO Trial Evaluating Venetoclax in Combination With Rituximab in Relapsed/Refractory CLL
Overall Survival With Nivolumab/Ipilimumab, or Nivolumab Alone, vs Ipilimumab in Advanced Melanoma
Surgeon-Initiated Gene-Expression Profile Testing in Early-Stage Breast Cancer and Time to Start of Chemotherapy
View More 
Advertisement
Most Read Stories
Adjuvant Chemotherapy vs Observation After Neoadjuvant Therapy and Radical Cystectomy for Bladder Cancer
Overall Survival With Nivolumab/Ipilimumab, or Nivolumab Alone, vs Ipilimumab in Advanced Melanoma
Osimertinib for EGFR-Positive NSCLC: The Phase III FLAURA Trial
FDA Approves First Biosimilar for the Treatment of Cancer
First-Line Gemcitabine/Docetaxel vs Doxorubicin in Advanced Soft-Tissue Sarcoma
A Gleason 6 Tumor: Is It Cancer, and Should It Be Treated?
ESMO 2017: New Data Confirms Superiority of Docetaxel-Based Triplet Therapy in Esophagogastric Cancer
ASCO 2017: LATITUDE Trial: Addition of Abiraterone to Standard Hormonal Therapy Improves Outcomes in Newly Diagnosed Metastatic Prostate Cancer
Osimertinib in First-Line Treatment of EGFR Mutation–Positive Advanced NSCLC
ESMO 2017: KEYNOTE-040 Evaluates Pembrolizumab in Head and Neck Cancer
© 2016 HSP News Service, L.L.C.